Sign in
4

Changes in Ownership

Karyopharm Therapeutics Inc. Filed Acc 0001209191-20-030615

Chief Executive Officer sold 15,000 shares at an average $19.32 ($289,841)

  • Chief Executive Officer acquired 15,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Kauffman Michael · Chief Executive Officer

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2020-05-15 Exercise or conversion : show line 1 in the form +7,500 $0.03 $248 763,989 I
2020-05-15 Sale : show line 2 in the form −7,500 $18.65 $139,841 756,489 I
2020-05-18 Exercise or conversion : show line 3 in the form +7,500 $0.03 $248 763,989 I
2020-05-18 Sale : show line 4 in the form −7,500 $20.00 $150,000 756,489 I
Open-market sales · 15,000 sh · avg $19.32 · $289,841

Table II: Derivative

2 lines
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2020-05-15 Exercise or conversion : show line 5 in the form Stock Option (right to buy) −7,500 $0.03 2020-10-21 7,500 7,857 I
2020-05-18 Exercise or conversion : show line 6 in the form Stock Option (right to buy) −7,500 $0.03 2020-10-21 7,500 357 I
Loading xslF345X03/doc4.xml…